DPP4 and lung carcinoma: TZD use in patients with greater DSCI [DSCI≧2, aHR 2.46 (1.25–4.82)] and DPP-4 inhibitors [aHR 2.24 (1.18–4.25)] had a higher risk of lung cancer (Supplementary Table S3).